83 related articles for article (PubMed ID: 9514263)
1. Prime region subsite specificity characterization of human cathepsin D: the dominant role of position 128.
Beyer BM; Dunn BM
Protein Sci; 1998 Jan; 7(1):88-95. PubMed ID: 9514263
[TBL] [Abstract][Full Text] [Related]
2. Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man.
Li T; Yowell CA; Beyer BB; Hung SH; Westling J; Lam MT; Dunn BM; Dame JB
Mol Biochem Parasitol; 2004 May; 135(1):101-9. PubMed ID: 15287591
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis.
Le Bonniec BF; Myles T; Johnson T; Knight CG; Tapparelli C; Stone SR
Biochemistry; 1996 Jun; 35(22):7114-22. PubMed ID: 8679538
[TBL] [Abstract][Full Text] [Related]
4. Exploration of subsite binding specificity of human cathepsin D through kinetics and rule-based molecular modeling.
Scarborough PE; Guruprasad K; Topham C; Richo GR; Conner GE; Blundell TL; Dunn BM
Protein Sci; 1993 Feb; 2(2):264-76. PubMed ID: 8443603
[TBL] [Abstract][Full Text] [Related]
5. Redesign of the substrate specificity of human cathepsin D: the dominant role of position 287 in the S2 subsite.
Scarborough PE; Dunn BM
Protein Eng; 1994 Apr; 7(4):495-502. PubMed ID: 7913221
[TBL] [Abstract][Full Text] [Related]
6. Subsite preferences of pepstatin-insensitive carboxyl proteinases from bacteria.
Narutaki S; Dunn BM; Oda K
J Biochem; 1999 Jan; 125(1):75-81. PubMed ID: 9880800
[TBL] [Abstract][Full Text] [Related]
7. S3 to S3' subsite specificity of recombinant human cathepsin K and development of selective internally quenched fluorescent substrates.
Alves MF; Puzer L; Cotrin SS; Juliano MA; Juliano L; Brömme D; Carmona AK
Biochem J; 2003 Aug; 373(Pt 3):981-6. PubMed ID: 12733990
[TBL] [Abstract][Full Text] [Related]
8. Differences in substrate specificities between cysteine protease CPB isoforms of Leishmania mexicana are mediated by a few amino acid changes.
Juliano MA; Brooks DR; Selzer PM; Pandolfo HL; Judice WA; Juliano L; Meldal M; Sanderson SJ; Mottram JC; Coombs GH
Eur J Biochem; 2004 Sep; 271(18):3704-14. PubMed ID: 15355348
[TBL] [Abstract][Full Text] [Related]
9. Electrostatic switches that mediate the pH-dependent conformational change of "short" recombinant human pseudocathepsin D.
Goldfarb NE; Lam MT; Bose AK; Patel AM; Duckworth AJ; Dunn BM
Biochemistry; 2005 Dec; 44(48):15725-33. PubMed ID: 16313175
[TBL] [Abstract][Full Text] [Related]
10. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
11. Effect of secondary substrate binding in penicillopepsin: contributions of subsites S3 and S2' to kcat.
Hofmann T; Allen B; Bendiner M; Blum M; Cunningham A
Biochemistry; 1988 Feb; 27(4):1140-6. PubMed ID: 3284578
[TBL] [Abstract][Full Text] [Related]
12. The specificity of prolyl endopeptidase from Flavobacterium meningoseptum: mapping the S' subsites by positional scanning via acyl transfer.
Bordusa F; Jakubke HD
Bioorg Med Chem; 1998 Oct; 6(10):1775-80. PubMed ID: 9839007
[TBL] [Abstract][Full Text] [Related]
13. S2' substrate specificity and the role of His110 and His111 in the exopeptidase activity of human cathepsin B.
Krupa JC; Hasnain S; Nägler DK; Ménard R; Mort JS
Biochem J; 2002 Feb; 361(Pt 3):613-9. PubMed ID: 11802791
[TBL] [Abstract][Full Text] [Related]
14. Cleavage efficiency of the novel aspartic protease yapsin 1 (Yap3p) enhanced for substrates with arginine residues flanking the P1 site: correlation with electronegative active-site pockets predicted by molecular modeling.
Olsen V; Guruprasad K; Cawley NX; Chen HC; Blundell TL; Loh YP
Biochemistry; 1998 Mar; 37(9):2768-77. PubMed ID: 9485427
[TBL] [Abstract][Full Text] [Related]
15. Exploring the binding preferences/specificity in the active site of human cathepsin E.
Rao-Naik C; Guruprasad K; Batley B; Rapundalo S; Hill J; Blundell T; Kay J; Dunn BM
Proteins; 1995 Jun; 22(2):168-81. PubMed ID: 7567964
[TBL] [Abstract][Full Text] [Related]
16. Active subsite properties, subsite residues and targeting to lysosomes or midgut lumen of cathepsins L from the beetle Tenebrio molitor.
Damasceno TF; Dias RO; de Oliveira JR; Salinas RK; Juliano MA; Ferreira C; Terra WR
Insect Biochem Mol Biol; 2017 Oct; 89():17-30. PubMed ID: 28838758
[TBL] [Abstract][Full Text] [Related]
17. Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors.
Majer P; Collins JR; Gulnik SV; Erickson JW
Protein Sci; 1997 Jul; 6(7):1458-66. PubMed ID: 9232647
[TBL] [Abstract][Full Text] [Related]
18. Probing cathepsin K activity with a selective substrate spanning its active site.
Lecaille F; Weidauer E; Juliano MA; Brömme D; Lalmanach G
Biochem J; 2003 Oct; 375(Pt 2):307-12. PubMed ID: 12837132
[TBL] [Abstract][Full Text] [Related]
19. Modification of the substrate specificity of porcine pepsin for the enzymatic production of bovine hide gelatin.
Galea CA; Dalrymple BP; Kuypers R; Blakeley R
Protein Sci; 2000 Oct; 9(10):1947-59. PubMed ID: 11106168
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of neprilysin (EC 3.4.24.11) S2' subsite.
Dion N; Cohen P; Crine P; Boileau G
FEBS Lett; 1997 Jul; 411(1):140-4. PubMed ID: 9247159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
